Bridgebio Pharma, INC 10-Q quarterly reports

BridgeBio Pharma's Q1 2026 results show significant revenue growth driven by product sales, alongside increased operating expenses and continued net losses.

BridgeBio Pharma reports significant revenue growth in Q3 2025 driven by strong Attruby sales and strategic licensing milestones, despite continued net losses.

BridgeBio Pharma reported increased net product revenue from its newly approved therapies, Attruby and Beyonttra, but also a significant rise in net losses for the first half of 2025.

BridgeBio Pharma's Q1 2025 results highlight the successful commercial launch of Attruby and Beyonttra, alongside strategic financial maneuvers including a $575 million note issuance and debt repayment.

BridgeBio Pharma's Q3 2024 results show a significant increase in revenue due to licensing agreements, but the company expresses substantial doubt about its ability to continue as a going concern.

BridgeBio Pharma's Q2 2024 results include a significant gain from the deconsolidation of a subsidiary and updates on strategic licensing agreements and financing activities.

BridgeBio Pharma's first quarter of 2024 saw a significant revenue increase due to new licensing agreements, despite a net loss.